April 26, 2026 FDA Grants Priority Review Vouchers for Psychedelic Drugs to Treat Depression and PTSD Under Trump Administration Plan
April 23, 2026 Trump Announces Drug Pricing Deal With Regeneron, Including Medicaid Price Cuts, $225 Praluent and $27B U.S. Investment
April 22, 2026 Title: Roche’s Fenebrutinib Shows Promise in MS Trials — But Safety Concerns Loom Ahead of FDA Review
April 21, 2026 Title: Trump Administration Urges States to Verify Medical Providers in High-Risk Areas to Combat Healthcare Fraud
